PHARMOSA BIOPHARM INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 77.4 TWD | +1.04% |
|
+0.91% | -12.05% |
| 05-15 | Pharmosa Biopharm Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 03-28 | Pharmosa Biopharm Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | 314.5 10.16K 24.56K | Capitalization | 10.31B 333B 805B |
|---|---|---|---|---|---|
| Net income 2022 | -267M -8.63B -20.85B | Net income 2023 | 8M 258M 625M | EV / Sales 2022 | - |
| Net cash position 2022 | 651M 21.04B 50.86B | Net cash position 2023 | 830M 26.81B 64.79B | EV / Sales 2023 | 30,156,637 x |
| P/E ratio 2022 |
-23.5
x | P/E ratio 2023 |
1,257
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.54% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.04% | ||
| 1 week | +0.91% | ||
| Current month | +1.31% | ||
| 1 month | +7.80% | ||
| 3 months | -32.70% | ||
| 6 months | -12.74% | ||
| Current year | -12.05% |
1 week
76.30
78.30
1 month
66.5082.70
Current year
64.10125.50
1 year
64.10162.00
3 years
31.00162.00
5 years
31.00162.00
10 years
31.00162.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pei Kan
CEO | Chief Executive Officer | - | 31/03/18 |
Shu Ping Yang
DFI | Director of Finance/CFO | - | 31/05/15 |
Ko Chieh Chen
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Jen Wu
BRD | Director/Board Member | - | 09/01/22 |
Ko Jui Shih
BRD | Director/Board Member | - | 24/10/21 |
Wen Chang Chang
BRD | Director/Board Member | - | 09/01/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/06/24 | 77.4 | +1.04% | 151,498 |
| 04/06/24 | 76.6 | -0.13% | 211,396 |
| 03/06/24 | 76.7 | +0.39% | 208,549 |
| 31/05/24 | 76.4 | -0.13% | 145,242 |
| 30/05/24 | 76.5 | -0.26% | 273,316 |
End-of-day quote Taipei Exchange, June 04, 2024
More quotes
Pharmosa Biopharm Inc is a Taiwan-based company mainly engaged in the research and development of new drugs. The main products include L606, for the treatment of Category I pulmonary arterial hypertension (PAH); L606, for the treatment of Category III pulmonary hypertension caused by interstitial lung disease (PH-ILD); L606, for the treatment of chronic thromboembolic Category IV pulmonary hypertension (CTEPH); L608, for the treatment of Category I pulmonary arterial hypertension (PAH).
| 1st Jan change | Capi. | |
|---|---|---|
| -12.05% | 305M | |
| +55.70% | 55.7B | |
| +41.08% | 39.91B | |
| -5.39% | 39.57B | |
| -5.56% | 28.16B | |
| +16.46% | 26.3B | |
| -20.56% | 18.94B | |
| +33.03% | 12.17B | |
| +25.85% | 12.12B | |
| +2.72% | 12.12B |
- Stock Market
- Equities
- 6875 Stock